The FDA has introduced a new expedited drug program, which has raised legal questions and concerns among various stakeholders. Some lawmakers and drugmakers have expressed worries about the program, with certain lawmakers investigating the program and others raising concerns about its potential risks. The program appears to be already in use, with at least one drug approved under the accelerated review process.